Table 1.
Characteristics of individuals with Mycoplasma genitalium (MG) infections by sex
| Total (n=502) n (%) |
Female (n=315) n (%) |
Male (n=187) n (%) |
|
|---|---|---|---|
| Age at diagnosis | |||
| < 20 years | 75 (14.9) | 63 (20.0) | 12 (6.4) |
| 20–29 years | 273 (54.4) | 170 (54.0) | 103 (55.1) |
| 30–39 years | 115 (22.9) | 63 (20.0) | 52 (27.8) |
| ≥ 40 years | 39 (7.8) | 19 (6.0) | 20 (10.7) |
| Race/Ethnicitya | |||
| Non-Hispanic Black | 225 (46.9) | 133 (43.8) | 92 (52.3) |
| Hispanic | 199 (41.5) | 139 (45.7) | 60 (34.1) |
| Other | 56 (11.7) | 32 (10.5) | 24 (13.6) |
| Sexual partnersa | |||
| Females | 124 (26.8) | 2 (0.7) | 122 (71.3) |
| Males | 322 (69.6) | 281 (96.2) | 41 (24.0) |
| Females and males | 17 (3.7) | 9 (3.1) | 8 (4.7) |
| Source of specimen | |||
| Urine | 334 (66.5) | 152 (48.2) | 182 (97.3) |
| Anogenital swab | 168 (33.5) | 163 (51.8) | 5 (2.7) |
| Living with HIVa | |||
| Yes | 39 (9.4) | 14 (5.6) | 25 (15.5) |
| Isolated MG infectionb | |||
| Yes | 216 (67.5) | 135 (66.1) | 81 (69.8) |
| Coinfection at time of MG diagnosisa | |||
| Chlamydia trachomatis | 57 (12.4) | 40 (13.9) | 17 (9.8) |
| Neisseria gonorrhoeae | 31 (6.7) | 13 (4.5) | 18 (10.4) |
| Trichomonas vaginalis | 32 (8.5) | 29 (11.6) | 3 (2.4) |
| Syphilis | 6 (1.5) | 0 (0) | 6 (3.8) |
| Bacterial vaginosis | 45 (53.6) | 45 (53.6) | - |
| Hospital testing location | |||
| Primary Care | 82 (16.3) | 60 (19.0) | 22 (11.8) |
| Obstetrics/Gynecology | 84 (16.7) | 84 (26.7) | - |
| Infectious Diseases | 150 (29.9) | 39 (12.4) | 111 (59.4) |
| Urgent Care/Emergency Department | 165 (32.9) | 116 (36.8) | 49 (26.2) |
| Other | 21 (4.2) | 16 (5.1) | 5 (2.7) |
| Clinical presentation | |||
| Asymptomatic | 181 (36.1) | 113 (35.9) | 68 (36.4) |
| Urethritis | 148 (29.5) | 31 (9.8) | 117 (62.6) |
| Vaginal symptoms | 142 (28.3) | 142 (45.1) | - |
| Pelvic inflammatory disease | 23 (4.6) | 23 (7.3) | - |
| Isolated lower abdominal pain | 9 (1.8) | 9 (2.9) | - |
| Abnormal vaginal bleeding | 9 (1.8) | 9 (2.9) | |
| Testicular pain | 3 (0.6) | - | 3 (1.6) |
| Initial treatmentc | |||
| Low-dose azithromycin | 156 (32.3) | 88 (29.2) | 68 (37.4) |
| High-dose azithromycin | 114 (23.6) | 93 (30.9) | 21 (11.5) |
| Moxifloxacin | 187 (38.7) | 85 (28.2) | 102 (56.0) |
| Doxycycline | 84 (17.4) | 49 (16.3) | 35 (19.2) |
| Other treatment | 30 (6.2) | 22 (7.3) | 8 (4.4) |
| Not treated | 19 (3.8) | 14 (4.4) | 5 (2.7) |
| Clinical outcome | |||
| Microbiologic cure | 156 (31.1) | 78 (24.8) | 78 (41.7) |
| Persistent infection | 113 (22.5) | 85 (27.0) | 28 (15.0) |
| No follow-up testing | 233 (46.4) | 152 (48.2) | 81 (43.3) |
Abbreviations: HIV, human immunodeficiency virus; MG, Mycoplasma genitalium; low-dose azithromycin, azithromycin 1 gram (g) for 1 dose; high-dose azithromycin, azithromycin 1g on day 1 followed by 500 milligrams (mg) daily on days 2–4; moxifloxacin, moxifloxacin 400 mg daily for at least 7 days; doxycycline, any duration of doxycycline 100 mg 2 times daily.
Missing data. Data presented in this table includes race/ethnicity data on 480 patients, sexual partners on 463, living with HIV on 413, isolated MG infection on 302, Chlamydia trachomatis and Neisseria gonorrhoeae testing on 460, Trichomonas vaginalis on 376, syphilis on 397, bacterial vaginosis on 84.
An isolated MG infection required negative testing for gonorrhea, chlamydia, trichomonas, and syphilis at the time of initial M. genitalium diagnosis.
Includes patients who received multiple treatment regimens.